Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Ulrika Ericson

Ulrika Ericson

Associate professor

Ulrika Ericson

Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort

Author

  • M. Obon-Santacana
  • N. Slimani
  • L. Lujan-Barroso
  • N. Travier
  • G. Hallmans
  • H. Freisling
  • P. Ferrari
  • M. C. Boutron-Ruault
  • A. Racine
  • F. Clavel
  • C. Saieva
  • V. Pala
  • R. Tumino
  • A. Mattiello
  • P. Vineis
  • M. Argueelles
  • E. Ardanaz
  • P. Amiano
  • C. Navarro
  • M. J. Sanchez
  • E. Molina Montes
  • T. Key
  • K. -T. Khaw
  • N. Wareham
  • P. H. Peeters
  • A. Trichopoulou
  • C. Bamia
  • D. Trichopoulos
  • H. Boeing
  • R. Kaaks
  • V. Katzke
  • W. Ye
  • M. Sund
  • Ulrika Ericson
  • Elisabet Wirfält
  • K. Overvad
  • A. Tjonneland
  • A. Olsen
  • G. Skeie
  • L. A. Asli
  • E. Weiderpass
  • E. Riboli
  • H. B. Bueno-De-Mesquita
  • E. J. Duell

Summary, in English

In 1994, acrylamide (AA) was classified as a probable human carcinogen by the International Agency for Research on Cancer. In 2002, AA was discovered at relatively high concentrations in some starchy, plant-based foods cooked at high temperatures. A prospective analysis was conducted to evaluate the association between the dietary intake of AA and ductal adenocarcinoma of the exocrine pancreatic cancer (PC) risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort using Cox regression modeling. EPIC includes > 500 000 men and women aged 35-75 at enrollment from 10 European countries. AA intake was estimated for each participant by combining questionnaire-based food consumption data with a harmonized AA database derived from the EU monitoring database of AA levels in foods, and evaluated in quintiles and continuously. After a mean follow-up of 11 years, 865 first incident adenocarcinomas of the exocrine pancreas were observed and included in the present analysis. At baseline, the mean dietary AA intake in EPIC was 26.22 mu g/day. No overall association was found between continuous or quintiles of dietary AA intake and PC risk in EPIC (HR:0.95, 95%CI:0.89-1.01 per 10 mu g/day). There was no effect measure modification by smoking status, sex, diabetes, alcohol intake or geographic region. However, there was an inverse association (HR: 0.73, 95% CI: 0.61-0.88 per 10 mu g/day) between AA intake and PC risk in obese persons as defined using the body mass index (BMI, >= 30 kg/m(2)), but not when body fatness was defined using waist and hip circumference or their ratio. Dietary intake of AA was not associated with an increased risk of PC in the EPIC cohort.

Department/s

  • Nutrition Epidemiology
  • Diabetes - Cardiovascular Disease
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2013

Language

English

Pages

2645-2651

Publication/Series

Annals of Oncology

Volume

24

Issue

10

Document type

Journal article

Publisher

Oxford University Press

Topic

  • Cancer and Oncology

Keywords

  • acrylamide
  • cohort
  • nutrition
  • pancreatic cancer

Status

Published

Research group

  • Nutrition Epidemiology
  • Diabetes - Cardiovascular Disease

ISBN/ISSN/Other

  • ISSN: 1569-8041